Compare Cassava Sciences Inc (FLNA) vs Corning Incorporated (GLW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Corning Incorporated — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while Corning Incorporated trades at $151.4 (market cap $131.65B). The key difference: Corning Incorporated is far larger — about 3341.4× Cassava Sciences Inc's market cap, and Corning Incorporated pays a 0.73% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Corning Incorporated for 35 Days on average.
| FLNA | GLW | |
|---|---|---|
Market Cap | $39.40M | $131.65B |
Volume | 759,018 | 8,992,522 |
Sector | Health | Technology |
52-Week High | $4.64 | $255.79 |
52-Week Low | $0.68 | $78.03 |
Typical Hold Time | 37 Days | 35 Days |
Enterprise Value | -$43.28M | $138.52B |
Dividend Yield | — | 0.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
GLW trades at $163.21, down 3.41% today, with a bullish technical signal and strong analyst support (56.75% buy ratings). Recent fundamentals show robust revenue growth to $15.63B in 2025 and net income of $1.60B, though valuation ratios like P/E of 70.43 appear elevated. The company secured a significant $3B+ fiber supply deal with AT&T, driving positive sentiment amid AI infrastructure demand.
Outlook is positive with earnings beats and a consensus price target of $171.25 offering ~5% upside. Key risks include high debt levels, patent litigation, and sensitivity to tech spending cycles. Institutional confidence remains high given operational cash flow strength and strategic positioning in fiber optics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →
